.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Covington
McKesson
AstraZeneca
Cerilliant
Chinese Patent Office
UBS
Medtronic
Argus Health

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018705

« Back to Dashboard
NDA 018705 describes NITROLINGUAL PUMPSPRAY, which is a drug marketed by Pohl Boskamp and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the NITROLINGUAL PUMPSPRAY profile page.

The generic ingredient in NITROLINGUAL PUMPSPRAY is nitroglycerin. There are thirty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.

Summary for 018705

Tradename:
2
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018705

Ingredient-typeNitrates
Physiological EffectVasodilation

Medical Subject Heading (MeSH) Categories for 018705

Suppliers and Packaging for NDA: 018705

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NITROLINGUAL
nitroglycerin
AEROSOL;SUBLINGUAL 018705 NDA Wilshire Pharmaceuticals, Inc. 52536-300 52536-300-20 1 BOTTLE in 1 CARTON (52536-300-20) > 200 SPRAY, METERED in 1 BOTTLE
NITROLINGUAL
nitroglycerin
AEROSOL;SUBLINGUAL 018705 NDA Jacksonville Pharmaceuticals, Inc. 70003-300 70003-300-20 1 BOTTLE in 1 CARTON (70003-300-20) > 200 SPRAY in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:AEROSOL;SUBLINGUALStrength0.4MG/SPRAY
Approval Date:Oct 31, 1985TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;SUBLINGUALStrength0.4MG/SPRAY
Approval Date:Jan 10, 1997TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Mar 14, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:ANGINA PECTORIS

Expired Orange Book Patents for NDA: 018705

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pohl Boskamp
NITROLINGUAL PUMPSPRAY
nitroglycerin
SPRAY, METERED;SUBLINGUAL018705-002Jan 10, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Merck
Baxter
Cantor Fitzgerald
Novartis
Citi
AstraZeneca
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot